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Abstract 
  Plasma apolipoprotein E (apoE) is a 34-kDa polymorphic protein, which has 
atheroprotective actions by clearing remnant lipoproteins and sequestering excess cellular 
cholesterol.  Low or dysfunctional apoE is a risk factor for hyperlipidaemia and atherosclerosis, and 
for restenosis after angioplasty.  Here, in short-term studies designed to establish proof-of-principle, 
we investigate whether encapsulated recombinant Chinese hamster ovary (CHO) cells can secrete 
wild-type apoE3 protein in vitro and then determine whether peritoneal implantation of the 
microcapsules into apoE-deficient (apoE
-/-) mice reduces their hypercholesterolaemia.   
  Recombinant CHO-E3 cells were encapsulated into either alginate poly-L-lysine or 
alginate polyethylenimine/polybrene microspheres.  After verifying stability and apoE3 secretion, 
the beads were then implanted into the peritoneal cavity of apoE
-/- mice; levels of plasma apoE3, 
cholesterol and lipoproteins were monitored for up to 14 days post-implantation.  
  Encapsulated CHO-E3 cells continued to secrete apoE3 protein throughout a 60-day 
study period in vitro, though levels declined after 14 days.  This cell-derived apoE3 was 
biologically active.  When conditioned medium from encapsulated CHO-E3 cells was incubated 
with cultured cells pre-labelled with [
3H]-cholesterol, efflux of cholesterol was 2-4 times greater 
than with normal medium (at 8 h, for example, 7.4±0.3% vs. 2.4±0.2% of cellular cholesterol; 
P<0.001).  Moreover, when secreted apoE3 was injected intraperitoneally into apoE
-/- mice, apoE3 
was detected in plasma and the hyperlipidaemia improved.  Similarly, when alginate 
polyethylenimine/polybrene capsules were implanted into the peritoneum of apoE
-/- mice, apoE3 
was secreted into plasma and at 7 days total cholesterol was reduced, whilst atheroprotective high-
density lipoprotein (HDL) increased.  In a second study, apoE was detectable in plasma of 5 mice 
treated with alginate poly-L-lysine beads, 4 and 7 days post-implantation, though not at day 14.  
Furthermore, their hypercholesterolaemia was reduced, while HDL was clearly elevated in all mice 
at days 4 and 7 (from 18.4±6.2% of total lipoproteins to 31.1±6.8% at 7 days; P<0.001); however, 
these had rebounded by day 14, possibly due to the emergence of anti-apoE antibodies. 
  We conclude that microencapsulated apoE-secreting cells have the potential to ameliorate 
the hyperlipidaemia of apoE deficiency, but that the technology must be improved to become a 
feasible therapeutic to treat atherosclerosis.   3
1.  Introduction 
Plasma apolipoprotein (apo) E is a 34-kDa polymorphic protein with several anti-atherogenic 
actions, including the clearance of remnant lipoproteins and promotion of cholesterol efflux from 
cells [1,2].  The common dysfunctional isoforms, apoE2 (C112, C158) and apoE4 (R112, R158), 
differ in two amino acid positions from the most prevalent or wild-type protein, apoE3 (C112, 
R158), and produce recessive (Type III) and dominant hyperlipidaemias, respectively [2,3].  ApoE4 
is also a risk factor for restenosis [4] and smoking-related heart disease [5].  Infusing apoE into 
hypercholesterolaemic rabbits regresses atherosclerotic lesions [6], while apoE transgenic mice 
resist dietary or diabetic hyperlipidaemia [7,8].  In contrast, apoE-deficient mice (apoE
-/-) have 
gross hyperlipidaemia with elevated very-low- (VLDL), intermediate- (IDL) and low-density 
lipoproteins (LDL) and develop spontaneous atherosclerosis [9].  
  Although considerable progress has been made in the prevention and treatment of 
atherosclerosis, new approaches are still needed.  These include systemic gene therapy to 
overexpress proteins that directly or indirectly inhibit atherogenesis and/or stabilize susceptible 
lesions.  Indeed, the principle of apoE gene transfer to treat dyslipidaemia and atherosclerosis using 
adenoviral vectors is already established by several laboratories, including our own [10].  However, 
non-viral transfer strategies have been relatively neglected [11-13]. 
  One approach to deliver therapeutic proteins is to encapsulate genetically engineered cells 
within semi-permeable membranes.  Alginate mixed with certain polymers is widely used to 
produce capsules and is a cheap and accessible technology for non-specialized laboratories.  The 
microcapsules have good biocompatibility and their pore size, which can be manipulated, allows 
nutrients to enter while excluding T-lymphocytes or antibody infiltration [14-21].  Potentially, this 
cell-therapy approach circumvents several problems associated with alternative systems, including 
inefficient gene transfer or a failure to sustain gene expression.  In the present study, we encapsulate 
recombinant cells expressing human apoE3 into alginate-based microspheres and confirm in vitro 
that apoE3 protein is secreted and is biologically active.  Moreover, when the capsules were 
implanted into the peritoneal cavity of apoE
-/- mice, apoE was readily detected in plasma and reduced 
total cholesterol levels, while increasing anti-atherogenic high-density lipoprotein (HDL).  We 
conclude that implantation of encapsulated apoE3-secreting cells can potentially reverse 
hyperlipidaemia.  However, the technology must be improved and refined before routine use, 
particularly for long-term use to help retard or regress atherosclerosis.   4
2.  Materials and methods  
2.1.  Recombinant cells secreting human apoE3  
Chinese hamster ovary cells were stably transfected with human apoE3 cDNA (CHO-E3 cells) 
using the p7055 high-expression vector, which contains the selectable marker gene, dihydrofolate 
reductase (DHFR) [22].  The CHO-E3 cells were cultured in humidified 5% CO2  at 37 °C in 
Iscove’s modified DMEM media supplemented with 2 mM glutaMAX, 100 U/ml penicillin, 100 
µg/ml streptomycin, 1% non-essential amino acids (all from Life Technologies; henceforth termed 
‘Iscove’s medium’) and 10% dialysed fetal bovine serum (FBS, Sigma), but lacking hypoxanthine 
and thymidine.  Conceivably, gene loss or silencing could ensue when the encapsulated CHO-E3 
cells are implanted into mice, as selection pressure on the DHFR gene is absent.  However, this was 
not observed when a DHFR-containing construct was used to express a neurotrophic factor [23]; 
nor did it occur when we cultured CHO-E3 cells in non-selection medium (unpublished data). 
 
2.2.  ApoE3 protein preparation and injection into apoE-deficient mice 
To prepare apoE3 protein for injection, recombinant CHO-E3 cells were cultured for 72 h in serum-
free CD-CHO medium (Life Technologies) and the media concentrated and dialysed against PBS 
by ultrafiltration (VIVASPIN, 30,000 MWCO; Vivascience).  Aliquots containing 50 µg apoE3 
were sterile-filtered and snap-frozen in liquid nitrogen for storage at -80°C.  Although such 
preparations may contain some CHO-derived proteins >30-kDa, we did not attempt to purify the 
apoE further, since there is good evidence that this can reduce bioactivity [24,25].  Two groups of 
adult female apoE
–/– mice (10-12 weeks old; provided by GlaxoSmithKline, Stevenage, UK) [9,13]) 
were given intraperitoneal injections of 50 µg apoE3 in 200 µl PBS.  The first group (n=3) was 
injected once, followed by tail-bleeds at 1, 2, 4 and 24 h, while the second (n=3) was injected daily 
for 4 days with tail bleeds on day 2 and day 5 (termination).  Control mice received PBS alone.  
Blood was clotted on ice for 2-3 h and the serum stored at –80 °C for subsequent analyses. 
 
2.3.  Microencapsulation and characterization of alginate beads 
Sodium alginate was purchased from Kelco International (Manugel; mannuronic:guluronic ratio of 1) 
and purified further by charcoal filtration, while coating reagents were from Sigma-Aldrich.  Non-
coated alginate (Alg) beads were prepared by suspending CHO-E3 cells (4-12 x 10
6 cells) in 3 ml of 
1.5% purified alginate and 3.6% sorbitol and extruding droplets with a concentric airflow through a 
23G needle at 1.5 ml/min into a gelling solution of 0.1 M CaCl2 in 0.15 M NaCl, pH 7.4.  These 
beads were used to make two types of coated beads.  The first were coated with polyethyleneimine   5
(PEI ) and polybrene (PB, hexadimethrine bromide) by washing the beads in 3.6% sorbitol, 0.33% 
methylcellulose (tylose MH 1000) and 10 mM HEPES for 2-3 min and then adding PEI/PB 
stepwise with stirring to final concentrations of 0.1% and 0.05%, respectively.  After further 
washing, 3% alginate was added to a final concentration of 0.03% and, following successive washes 
with sterile water and Iscove’s medium, the beads were transferred to culture flasks.  The second set 
of beads was coated with poly-L-lysine (PLL, 30-70 kDa) at a final concentration of 0.05% in 0.15 
M NaCl.  The microcapsules were washed 3 times in calcium-free Krebs-Ringer buffer (KRB), 
incubated in alginate (0.2%) for 5 min and then in 1 mM EGTA for 10 min, before washing in KRB 
and suspension in Iscove’s medium. 
  Both Alg-PEI/PB and Alg-PLL beads were characterized further.  Mechanical stability was 
assessed by preparing coated and uncoated beads in 1% blue-dextran (2,000 kDa, Amersham Plc) 
and then shaking overnight with 500 µm diameter glass balls.  Absorbance of the supernatants was 
measured at 620 nm.  To measure cell proliferation the beads were first disrupted by incubation 
with 0.02% EDTA for 20 min at 37 °C and passage through a 23G needle and the liberated cells 
collected by brief centrifugation.  Cell nuclei were isolated by incubation with 0.01% Triton X-100 
in PBS for 18 h at 4 °C, stained with propidium iodide and counted under a fluorescent microscope 
(Nikon Eclipse TE 200).  Finally, we measured apoE3 secretion and cell leakage from encapsulated 
cells by culturing the beads in nylon mesh strainers (BD Falcon) within 6-well plates.  At regular 
intervals, the supernatant was collected to measure 24 h secretions of apoE3, while any cells 
escaping from the beads and becoming adherent were dissolved in 0.1 M NaOH and quantified by 
protein assay (Bradford reagent; Bio-Rad Laboratories).  
 
2.4.  Cholesterol efflux  
The bioactivity of apoE3 secreted from capsules was examined by measuring their ability to 
promote cellular cholesterol efflux [26].  Wild-type CHO cells were seeded overnight in 12-well 
plates (2 x 10
5 cells/well) and labelled by incubating for 24 h in 1 ml Iscove’s medium 
supplemented with 5% FBS and 1 µCi [
3H]-cholesterol.  The cells were then equilibrated overnight 
in Iscove’s medium plus 1% fatty acid-free albumin and cholesterol efflux initiated by adding 
conditioned CD-CHO medium from encapsulated CHO-E3 cells (1 ml; 24 h collection) for 2, 4 or 8 
h; medium from wild-type cells was used as control.  At each time point, efflux medium was 
collected, centrifuged for 1 min at 10,000 g and an aliquot taken for [
3H] measurement, while the 
cell monolayers were dissolved in 0.1 M NaOH to quantify cellular [
3H]-cholesterol.  The 
percentage cholesterol efflux was calculated as dpmmedium / (dpmmedium + dpmcells) x 100%.  
   6
2.5. Intraperitoneal implantation of encapsulated CHO-E3 cells 
In a pilot experiment, three mice (mice 1-3) received intraperitoneal injections of ~9 x 10
6 cells 
encapsulated in Alg-PEI/PB beads (900 µl).  In the second study, 5 mice (mice A-E) were injected 
with ~10 x 10
6 cells in 900 µl of Alg-PLL beads, while 5 control mice (mice a-e) received empty 
beads.  All animals were killed one or two weeks post-implantation by CO2 inhalation.  In some 
cases, beads were retrieved by washing the peritoneal cavity with sterile saline and then were 
cultured for 10 days to verify their integrity and to confirm continuous secretion of apoE3. 
 
2.6.  Lipid analyses of mouse serum  
Lipoproteins in serum (2 µl) were separated by electrophoresis in Sebia alkaline-buffered agarose 
gels (YSI, Farnborough, UK),  measuring relative concentrations by scanning densitometry (Bio-
Rad GS-670 with Molecular Analyst Version 1.4 software) after Sudan Black staining [10].  Total 
cholesterol was assayed in 96-well plates (INFINITY cholesterol reagent; Sigma-Aldrich).   
 
2.7.  Detection of human apoE and anti-apoE antibodies in mouse serum 
Human apoE3 secreted into serum of apoE
-/- mice was detected by Western blotting and quantified 
by a two-antibody sandwich ELISA, both as described previously [10].  To detect any anti-human 
apoE antibodies, human apoE3 (1 µg/lane) was transferred to Hybond–PVDF membranes by 
Western blotting and individual lanes hybridized with 2.5 µl of test mouse serum in 600 µl of buffer 
containing 2.5% milk powder and 0.05% Tween 20.  Detection was with a goat anti-mouse–HRP 
secondary antibody using a mouse monoclonal antibody against human apoE3 as a positive control.  
 
2.8.  Statistics 
Results are expressed as means ± S.D.  Statistical differences between means were analyzed by 
Student’s paired or unpaired t-test, as appropriate; P<0.05 was considered significant.  
 
3.  Results 
3.1.  ApoE3 injections into apoE
-/- mice 
Human apoE3 protein (Materials and methods) was injected into the peritoneal cavity of two groups of 
apoE
-/- mice.  The first group (n=3) received a single injection of 50 µg.  At 1 h apoE3 was readily 
detected in serum, appeared to have peaked at about 6 µg/ml by 4 h (2/3 mice having less apoE3 at 4 h 
than 2 h), and at 24 h had declined markedly to <5% of the peak value (Fig. 1a).  The second  group   7
(n=3) received daily injections of 50 µg apoE3 for 4 days, collecting blood just prior to injections at 0 
and 2 days, and at termination, 24 h post-injection (5 days).  At 2 days, serum apoE3 was about 0.8 
µg/ml but ~30% lower at 5 days (Fig. 1b).  However, serum cholesterol was significantly reduced in 
the treated mice at termination, falling from 523±40 mg/dl to 399±18 mg/dl (P<0.05) (Fig. 1c).  In 
addition, when the individual lipoprotein fractions were analysed by agarose gel electrophoresis there 
was a significant increase (P<0.05) in the proportion of atheroprotective HDL present (Fig. 1d).   
 
3.2.  Secretion of human apoE3 from encapsulated CHO-E3 cells in vitro 
Recombinant CHO-E3 cells were encapsulated into Alg-PEI/PB beads or uncoated beads at a 
density of 12 x 10
6 cells/ ml alginate and cultured for 10 days.  ApoE3 was secreted continuously at 
an approximately constant rate from both types of beads, suggesting that the cross-linking 
polymeric coating did not impair secretion (Fig. 2a).  In a second study, Alg-PLL beads containing 
CHO-E3 cells at an initial density of 4 x 10
6 cells/ml alginate were cultured for 2 months; the cells 
remained viable and secreted apoE3 throughout the study period.  However, while the amount of 
secreted apoE3 increased steadily for the first 2 weeks, peaking at nearly 1 µg/ml/24 h, it declined 
thereafter to <0.1 µg/ml/24 h at 8 weeks (Fig. 2b).   
The ability of CHO-E3 cells to proliferate post-encapsulation was studied and also bead 
stability itself.  As judged by counting isolated nuclei in 1 ml beads, CHO-E3 cells were capable of 
~6-fold proliferation.  Thus, in uncoated beads cell numbers (x 10
-5) increased from 2.6±0.1 at day 
0 to 17.4±1.2 at day 10, while the corresponding increases for coated Alg-PLL beads were from 
5.1±0.2 to 14.5±0.9 and for Alg-PEI/PB beads from 5.2±0.2 to 20.1±0.2.  Mechanical stability was 
assessed by leakage of encapsulated blue dextran in an abrasion test.  As this high molecular weight 
polymer cannot diffuse out of intact beads, its appearance in the supernatant following agitation of 
the microcapsules with glass balls reflects bead rupture.  As shown in Fig. 2c, uncoated beads were 
much more fragile (P<0.001), whereas coated beads readily withstood the test with no clear 
difference between them (P>0.05).  To evaluate the long-term stability of beads in culture, the 
protein content of leaked cells, which form colonies on the surface of the plate, was measured after 
10 days.  The cell protein leaked from uncoated beads was 68.7±3.1 µg, whereas the coated Alg-
PLL and Alg-PEI/PB beads leaked 5.0±0.6 µg and 4.0±1.1 µg protein, respectively (both P<0.001).  
 
3.3.  Encapsulated CHO-E3 cells secrete biologically active human apoE3  
To verify that the apoE3 secreted by encapsulated cells was biologically active, cholesterol efflux 
experiments were undertaken.  Wild-type CHO cells were radiolabelled with [
3H]-cholesterol and   8
incubated with conditioned serum-free CD-CHO medium from encapsulated CHO-E3 cells, 
containing 624±3.1 ng of secreted apoE3.  At each time studied, 2, 4 and 8 h, the capsule-
conditioned medium promoted 2-4 times more cholesterol efflux than control medium; at 8 h, for 
example,  7.4±0.3% of cell cholesterol was effluxed compared to 2.4±0.2% (P<0.001) (Fig. 2d). 
 
3.4.  Intraperitoneal implantation of encapsulated CHO-E3 cells  
In the pilot study, CHO-E3 cells encapsulated in Alg-PEI/PB beads were cultured for 1 day and 
then implanted into the peritoneal cavity of three apoE
-/- mice (mice 1-3), collecting tail blood at 
days 2, 4 and 7.  In two animals (mice 2 and 3), apoE3 was detected in serum (35-80 ng/ml) 
throughout the study (Fig. 3a), and on day 7 their serum cholesterol had fallen by 13% and 19%, 
respectively (Fig. 3b).  In contrast, no apoE was detected in the serum of mouse 1 and its 
cholesterol level was slightly raised.  Analysis of the lipoproteins by agarose gel electrophoresis 
revealed that the proportion of HDL had risen in mice 2 and 3, but was unchanged in mouse 1 (Fig. 
3c).  Microcapsules were harvested from animals at 7 days post-implantation, re-cultured for 10 
days and then the media analyzed for human apoE3 by Western blotting.  All were positive, 
although mouse 1 gave a weak signal compared to mice 2 and 3 (Fig. 3d). 
In a second experiment, CHO-E3 cells were encapsulated in Alg-PLL beads and, following 
culture in vitro for 3 days, were implanted into five apoE
-/- mice, collecting tail bloods on days 4, 7 
and 14; five control mice received empty capsules.  ApoE3 was present in the serum of treated mice 
on days 4 and 7 at levels of 83±9 and 153±14 ng/ml, respectively, but was undetectable by day 14 
(Fig. 4a).  Western blots also confirmed the presence of human apoE3 in mouse serum at days 4 and 
7 only (Fig. 4b).  Consistent with these data, mean serum cholesterol levels decreased significantly 
on days 4 and 7 (P<0.001 and P<0.01, respectively; Fig. 4a), whereas agarose gel lipoprotein 
analysis revealed significant rises in the proportion of HDL (P<0.05 and P<0.05, respectively; Fig. 
4c); these both rebounded to pre-implantation levels at day 14 (Fig. 4a,c).  Finally, sera from treated 
mice at termination (day 14) were screened for antibodies against secreted human apoE3 by 
Western blot analysis. In all five mice, anti-apoE antibodies were present, apparently at somewhat 
different amounts, being highest in mouse D and lowest in mouse C, but were not detectable in the 
sera of control animals (Fig. 4d).  
 
4.  Discussion 
Here, we report the first use of encapsulated cell technology to reverse hyperlipidaemia, which if 
successful in long term studies should stabilize or regress atherosclerotic lesions.  Diverse viral and   9
non-viral gene transfer strategies are being developed to express therapeutic proteins, but many 
problems remain.  Increasingly, cell encapsulation technology is seen as an alternative possibility, 
particularly for patients with diabetes, neurodegenerative diseases (Alzheimer's and Parkinson's), or 
liver failure, and clinical trials are underway or planned [21,27,28].  The cell types tested include 
islets of Langerhans [29-31], hepatocytes [32,33], parathyroid cells [34] and dopamine-secreting 
cells [35,36], as well as cell lines genetically engineered to secrete bioactive proteins [37-41].   
Although allogeneic cells minimize immune responses and obviate potential for xenogenic virus 
spread, use of xenogeneic cells is common.  This includes clinical trials, for example, recombinant 
BHK cells to express human ciliary neurotrophic factor [23] and pancreatic or Sertoli cells from 
pigs to treat diabetes [42], while in rats a 2-year study to correct hypothyroidism using encapsulated 
pig parathyroid cells gave no immune responses or infections [43].  Alginate or agarose are the 
favoured polymers to produce permeable microcapsules, while thermoplastic materials are typically 
used for macrocapsule devices, such as hollow fibres or flat sheet membranes [19,44].  
  Our study evaluated whether peritoneal implantation of alginate microencapsulated 
recombinant CHO cells could deliver therapeutic levels of human apoE3 protein to apoE
-/- mice, a 
widely used model of hyperlipidaemia and atherosclerosis [9,10,13,45].  As a prerequisite, we injected 
CHO-cell derived apoE3 protein into their peritoneal cavities, as a bolus or repeated dose, and verified 
that apoE3 reached the plasma compartment.  Moreover, the repeat intraperitoneal injection regime 
significantly reduced total cholesterol, whilst increasing the level of atheroprotective HDL.  These 
findings agree with earlier data from intravenous bolus injections; total cholesterol fell by nearly 50% 
at termination (6 h), attributed to increased hepatic clearance of cholesterol-rich remnant lipoproteins, 
while HDL increased by 10-18% [46].  Why the HDL rises is unclear, although apoE can activate the 
cholesterol esterifying enzyme, LCAT, which is rate limiting for HDL maturation [47,48].   
Additionally, marked reductions in VLDL and IDL may release apoA-I for HDL assembly [49].  
Two different coatings were used to encapsulate CHO-E3 cells in alginate microspheres.  
One, poly-L-lysine, was initially studied in vitro using cells encapsulated at low density; after a 
short lag phase (days 1-4), perhaps an adaptation to the new environment, apoE secretion steadily 
increased as cells grew and divided in the Alg-PLL beads (days 5-10) before a plateau phase at 
confluence (days 11-15).  Thereafter, secretion fell, presumably due to cell overgrowth and poor 
nutrient supply, but remained continuous at low level throughout the two-month study (Fig. 2b).  
One option to overcome excess cell proliferation, and diminished secretion, is to encapsulate 
recombinant mouse C2C12 myoblasts.  These terminally differentiate into myotubes in low FCS, 
allowing implantation of non-dividing cells [50], although there is a need to increase expression by 
improving transfection vectors and to prevent immune responses [51,52].     10
The second coating, a polyethyleneimine-polybrene combination (PEI/PB) was chosen 
because PEI increases the mechanical stability of capsules [53,54], while the low molecular weight 
positively charged polybrene prevents cross-linking of individual microspheres by PEI.  These Alg-
PEI/PB capsules secreted apoE3 at levels very similar to uncoated beads, suggesting that the coat 
had little effect on permeability.  However, the beads differed markedly in stability, as judged by 
the abrasion test, since the uncoated capsules proved very fragile.  Alg-PEI/PB performed slightly 
better than Alg-PLL in this test, and also appeared superior for cell growth since cell numbers 
increased 3.8-fold in Alg-PEI/PB beads compared to 2.8-fold in Alg-PLL .  
Before studying encapsulated cells in vivo, we verified that the apoE secreted was 
biologically active.  As apoE atheroprotection relates, in part, to its sequestration of cellular 
cholesterol [1,3,55], we examined this function by adding encapsulated CHO-E3 cell-conditioned 
medium to cells pre-labelled with [
3H]-cholesterol.  This medium promoted 2-4-times more 
cholesterol efflux than control medium, confirming that secreted apoE3 was not inactivated during 
escape from the capsules.  A pilot in vivo study was then carried out, implanting CHO-E3 cells 
encapsulated in Alg-PEI/PB beads into the peritoneum of three apoE
-/- mice for 7 days.   In two 
animals, apoE3 was detected in plasma and was accompanied by clear elevations in HDL and 
modest reductions in total cholesterol (13% and 19%).  These changes were not seen in the third 
mouse and, when the capsules were retrieved, microscopy revealed that many were lysed and empty 
of cells.  This explains why no apoE was detected in plasma, but not why breakage occurred since 
all mice received capsules from the same batch and these were microscopically intact pre-
implantation.  Others have noted bead rupture [27,56], which is independent of the secreted protein 
or capsule coating, but although leakage of xenogeneic cells probably contributes to the overall 
inflammatory response, such cells are rapidly eliminated [23].  Some researchers omit liquefying 
the inner capsule with EGTA or citrate to minimize leakage, as this may promote instability.   
However, as a liquid inner alginate core provides more intracapsular space for cells to grow and 
nutrients to diffuse [14,16], we preferred to retain this standard step, although future studies could 
consider omission if capsule instability remained a problem. 
In a second in vivo study, CHO-E3 cells were encapsulated in Alg-PLL beads.  ApoE3 was 
secreted in all five treated mice at least until day 7 post-implantation.  Higher levels of plasma 
apoE3 were detected compared to the pilot study, perhaps because the beads were cultured longer 
before implantation, allowing the encapsulated cells more time to adapt and proliferate into their 
new environment.  The larger pore size of Alg-PLL compared to Alg-PEI/PB may also be important 
because apoE3 is secreted as lipidated particles of heterogeneous size [57]; conceivably very large 
particles may not cross the alginate-polymer barrier [53].  Nevertheless, the amount of apoE3 was   11
relatively low, with a peak of 154 ng/ml plasma compared to ~50 µg/ml in normal mice [58,59].  
This was not unexpected, however, as recombinant apoE is promptly sequestered by lipoproteins 
upon entry into the grossly hyperlipidaemic plasma of apoE-deficient mice, followed by rapid 
hepatic clearance of the particles [45].  Rapid removal has also been noted following apoE protein 
injections, both here (Fig. 1a,b) and by others [46].  In mouse, most liver-derived apoB is truncated 
(apoB-48, whereas human liver secretes only apoB-100), and as this variant structural protein for 
VLDL, IDL and LDL lacks the LDL-receptor binding domain, the particles require apoE for 
clearance [9,59], either via the LDL-receptor itself or LDL-receptor related protein (LRP) [2].  
Despite low plasma apoE3, total cholesterol was significantly decreased by 25-30% on days 
4 and 7, in addition to the rise in HDL.  The threshold concentration of plasma apoE needed for 
cholesterol homeostasis is uncertain.  The most detailed study, in which apoE
+/+ bone marrow was 
mixed with apoE
-/- marrow in increasing amounts and then transplanted into apoE
-/- recipient mice, 
suggests that 400 ng apoE/ml is the lower limit to fully normalize plasma cholesterol [58].  In 
contrast, only 0.6 ng apoE/ml is reported to maintain 40% reductions in plasma cholesterol for 16 
weeks following intramuscular injection of an apoE3-expressing plasmid [60], while apoE3-
secreting endothelial cells embedded in Matrigel significantly lowered cholesterol levels by 40-60% 
for over 3 months, even though apoE3 was not detected in plasma at any stage [45].  In our study, 
the mean reductions in plasma cholesterol at days 4 and 7 had rebounded at day 14 (Fig. 4a).  One 
explanation, not discussed in the other studies [45,58,60], might be the appearance of antibodies 
against apoE3, a neo-antigen in apoE
-/- mice, which we detected in the sera of treated mice 14 days 
post-implantation.  Indirect support for this possibility was our failure to detect apoE3 in plasma at 
day 14, despite finding that beads retrieved from the peritoneum continued to secrete apoE3 in 
vitro.  This implies that apoE3 was continuously produced in the treated mice, but was neutralized 
by mouse anti-human apoE antibodies.  Indeed, mouse C, which gave the weakest immune 
response, showed no rebound of total cholesterol and in fact was lower on day 14 (253 mg/dl) than 
on day 7 (281 mg/dl).  Note, however, that emergence of apoE antibodies is unlikely in alternative 
models that do not recognize apoE3 as foreign, including the double transgenic humanapoE2/apoE
-/- 
mouse, which mimics Type III hyperlipidaemia [61].   
One factor promoting antibody emergence might be a non-specific host inflammatory 
reaction to capsule constituents, as signs of immunogenicity were noted at retrieval, including some 
lymphocyte and macrophage adhesion to the capsule surface and early fibrotic overgrowth (data not 
shown).  This is important as fibrous tissue formation may physically impair effective secretion of 
therapeutic proteins, and also impede implant functioning by decreasing transfer of oxygen, 
nutrients and metabolites.  Intraperitoneal inflammatory reactions against capsules most likely relate   12
to alginate impurities, including pyrogens, endotoxins and mitogens, since ultrapure preparations 
can reduce fibrotic overgrowth to <10% [62].  Such an adjuvant action of alginate beads might 
explain why secreted apoE was apparently inactivated in our study, whereas in the work cited above 
[45,58,60] the hyperlipidaemia remained suppressed.  On the other hand, gene transfer studies using 
viral vectors also report emergence of apoE antibodies in apoE
-/- mice, 2-4 weeks after exposure to 
the protein [10,63,64], though this depends on the vector [65,66] and the tissue targeted [10].   
In conclusion, we have shown for the first time that implantation of microencapsulated 
apoE-secreting cells can ameliorate hyperlipidaemia.  Although our studies were short-term and 
designed only to demonstrate proof-of-principle, they also emphasize the need to improve capsule 
biocompatibility, a problem common to all encapsulated cell therapies.  Difficulties of standardizing 
alginate purity and of producing uniform capsules appear readily soluble, the latter by the use of 
automated machines [67], while progress is being made in developing immune-compatible cross-
linking coating polymers [20,21,68].  Other factors, such as choice of cell and site of transplantation 
are also under study [20,21].  Our hope is clear: that these advances will eventually allow routine 
encapsulated cell therapy in humans for short-term delivery of apoE3, pre- and post-angioplasty to 
protect against restenosis, and by analogy with conventional gene transfer approaches [10,13,49,63-
66], also for long-term delivery to stabilize or regress atherosclerotic lesions.  
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 Legends to Figures 
 
Fig 1.  Intraperitoneal apoE3 protein injections into apoE
-/- mice.  (a) A bolus injection of apoE3 (50 
µg) gave measurable levels of apoE3 in plasma throughout the 24 h study, with a maximum 
between 2-4 h (~6 µg/ml).  In a repeat dose regime, three mice received 4 daily intraperitoneal 
injections (50 µg apoE3) and plasma was analyzed at days 0, 2 and 5.  (b) ApoE3 protein was 
readily detected (0.25-0.85 µg/ml) and produced a significant ~25% reduction in cholesterol at 
termination (P<0.05) (c), while levels of atheroprotective HDL rose (P<0.05) (d).   
  
Fig 2. In vitro expression and release of human apoE3 from encapsulated CHO-E3 cells. (a) Cells 
were cultured for 10 days after encapsulation at high density (12 x 10
6 cells) in Alg-PEI/PB or 
alginate only beads (uncoated) for 10 days.  ApoE3 was secreted continuously at constant and 
comparable levels from both types of capsule.  (b) CHO-E3 cells were encapsulated at low density 
(4 x 10
6 cells) in Alg-PLL beads and cultured for 2 months.  The cells remained viable and 
proliferated within the capsules, which showed no breakage.  ApoE3 secretion increased to a 
maximum of 1 µg/ml/24 h at days 11-15, but steadily declined thereafter to <20 ng/ml/24 h at 2 
months. (c) Blue-dextran (1%) was incorporated inside uncoated and coated Alg-PLL and Alg-
PEI/PB capsules, which were then tested for mechanical stability by vigorously shaking overnight 
with glass beads.  Leakage from both coated beads was negligible (<5%), as judged by A620 
measurements of supernatants, whereas uncoated capsules were very fragile. (d) To verify that 
secreted apoE3 was bioactive, cholesterol efflux studies were carried out.  Wild-type CHO cells 
were pre-labelled with [
3H]-cholesterol and incubated with conditioned medium from encapsulated 
CHO-E3 cells for up to 8 h.  This medium promoted significantly more efflux at all time points 
compared to control medium.  Results shown are mean ± S.D. from triplicate samples.  **P<0.01, 
***P<0.001.  
 
Fig. 3.  Peritoneal implantation of encapsulated CHO-E3 cells in apoE
-/- mice.  In a pilot study, Alg-
PEI/PB beads were injected into the peritoneal cavity of three apoE
-/- mice (mice 1-3), collecting 
blood pre- and 2, 4 and 7 days post-implantation.  (a) ApoE3 was detected in plasma of mice 2 and 
3 (35-80 ng/ml), but not mouse 1.  (b) Mice 2 and 3 showed reductions in plasma total cholesterol 
of 13% and 19%, respectively, on day 7 compared to day, whereas (c) levels of  atheroprotective 
HDL clearly rose at days 2 and 7 as judged by agarose gel electrophoresis; these changes were not 
seen in plasma from mouse 1.  (d) When capsules were retrieved from the mice and cultured for 10 
days they maintained their integrity and continuously secreted apoE3 during this period.  Analysis   18
of 24 h medium collections by Western blotting confirmed apoE3 secretion, although the signal for 
mouse 1 was weaker than for mice 2 and 3.  
 
Fig. 4.  Peritoneal implantation of encapsulated CHO-E3 cells produces a less atherogenic plasma 
lipid profile in apoE
-/- mice.  Alg-PLL microcapsules containing CHO-E3 cells were implanted into 
the peritoneum of five apoE
-/- mice (A-E) for 2 weeks, collecting blood on days 0, 4, 7 and 14, 
while other mice (a-e) received empty beads. (a) ApoE3 was detected in plasma of all treated mice 
on days 4 and 7 (83±9 and 153±14 ng/ml), though not on day 14; this was confirmed (b) by 
Western blot analysis.  Plasma total cholesterol was significantly lowered by ~25% at days 4 and 7, 
but had rebounded at day 14 (a), while agarose gel electrophoresis (c) revealed significant increases 
in the proportion of HDL present at days 4 and 7 (P<0.05).  (d)  Sera from treated mice were 
screened for anti-apoE3 antibodies at termination (day 14).  All five mice gave positive antibody 
responses, at somewhat different levels, but none was detectable in the sera of control animals.  
Con, control anti-apoE antibody.  Where appropriate results are shown as means ± S.D.; *P<0.05, 
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